53. Motegrity


Active ingredient: prucalopride
Disease: chronic idiopathic constipation
Peak sales estimate: n/a
Approved: Dec. 17
Company: Shire

The scoop: Synergy Pharmaceuticals wasn’t able to seriously challenge Allergan’s Linzess in the market with Trulance, but now Shire is going to give it a try. It’ll be wielding Motegrity, a constipation treatment that works by stimulating muscle movement in the colon. Regulators OK’d the drug after an advisory panel endorsed it unanimously, voting 10-0 in favor of an approval and signaling its satisfaction with Shire data showing the drug didn’t come with the same cardiovascular safety risks as other products in its class of 5-HT4 treatments. The green light was also a win for Takeda, which will soon swallow Shire as part of a $62 billion buyout, and it should bring a little peace of mind to some Takeda investors that opposed the deal. — Carly Helfand


53. Motegrity

Suggested Articles

Biotech leaders criticized the dismissals of Chinese scientists from U.S. universities in a letter with more than 150 signatures.

In this week's EuroBiotech Report, Merck allies with Themis on vaccine R&D, Juvenescence raises $100 million and GSK files for anemia approval. 

In our EuroBiotech roundup this week, Scancell withdraws IND, Oxurion’s eye drug fails phase 2a and Abivax starts ulcerative colitis trial.